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ZEB2 drives immature T-cell lymphoblastic
leukaemia development via enhanced tumour-
initiating potential and IL-7 receptor signalling
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Tom Taghon10, Cedric S. Tremblay11, Magdaline Costa4, Morvarid Farhang Ghahremani1,2, Jelle De Medts10,
Sonia Bartunkova1, Katharina Haigh1,2,4, Claire Schwab12, Natalie Farla1,2,3, Tim Pieters1,2,3,9, Filip Matthijssens9,
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Viktor Janzen20, Matthew P. McCormack16, Richard B. Lock15, David J. Curtis11, Christine Harrison12, Geert
Berx2,3, Frank Speleman8, Jules P.P. Meijerink17, Jean Soulier7,8, Pieter Van Vlierberghe9 & Jody J. Haigh1,2,4
Early T-cell precursor leukaemia (ETP-ALL) is a high-risk subtype of human leukaemia that is
poorly understood at the molecular level. Here we report translocations targeting the zinc
finger E-box-binding transcription factor ZEB2 as a recurrent genetic lesion in immature/ETP-
ALL. Using a conditional gain-of-function mouse model, we demonstrate that sustained Zeb2
expression initiates T-cell leukaemia. Moreover, Zeb2-driven mouse leukaemia exhibit some
features of the human immature/ETP-ALL gene expression signature, as well as an enhanced
leukaemia-initiation potential and activated Janus kinase (JAK)/signal transducers and
activators of transcription (STAT) signalling through transcriptional activation of IL7R. This
study reveals ZEB2 as an oncogene in the biology of immature/ETP-ALL and paves the way
towards pre-clinical studies of novel compounds for the treatment of this aggressive subtype
of human T-ALL using our Zeb2-driven mouse model.
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T
-cell acute lymphoblastic leukaemia (T-ALL) arises due to
multiple genetic lesions in immature T cells leading to a
block in differentiation, increased survival and clonal
proliferative expansion of a malignant clone1,2. Despite the
improved survival rates because of intensified chemotherapy and
bone marrow transplantation, 20% of T-ALL patients still relapse
with little or no perspective for cure.
One particularly challenging subgroup of T-ALL is the LYL1þ /
immature/early T-cell precursor leukaemia (ETP-ALL)3,4.
Lymphoblasts of these patients exhibit gene expression profiles
similar to ETPs5,6, the most primitive T-cell progenitor cells
within the thymus. Although it has been recognized that a high
mutation load characterizes this heterogeneous subgroup7, the
nature of the driving oncogenic events remains largely unknown.
Strikingly, these immature leukaemia patients show inferior
survival rates as compared with the other T-ALL subgroups5,7.
The basis of this poor prognosis has yet to be identified, although
one potential contributing factor could reside in enhanced
leukaemic stem cell properties of this aggressive T-ALL subtype.
Here we report the identification of a recurrent
t(2;14)(q22;q32) translocation targeting the human ZEB2 locus
in immature/ETP-ALL, indicating that deregulation of ZEB2
expression can act as an initiating driver event for this aggressive
disease. ZEB2 is a member of the Zinc finger E-box-binding
family of transcription factors8,9, whose altered expression has
previously been correlated with the acquisition of cancer stem cell
properties10,11. Using a conditional Zeb2 gain-of-function mouse
model, we provide further evidence for a key oncogenic role of
ZEB2 in the biology of immature/ETP-ALL driven by enhanced
stem cell characteristics and activation of the IL7R-JAK/signal
transducers and activators of transcription (STAT) signalling
pathway.
Results
ZEB2 locus translocations in human immature/ETP-ALL.
Karyotyping of T-ALL samples revealed a novel chromosomal
translocation t(2;14)(q22;q32) (Fig. 1a) in two patients with a
typical immature/ETP-ALL immunophenotype5. Interestingly,
the BCL11B gene resides in chromosome band 14q32 and given
its implication in translocations leading to overexpression of
several bona fide T-ALL oncogenes, such as HOX11L2/TLX3,
HOXA13 (refs 12,13) and NKX2-5 (refs 14,15), we performed
fluorescence in situ hybridization (FISH) analysis using locus-
specific probes. This confirmed the disruption of the BCL11B
locus at 14q32 and suggested the presence of a novel ETP-ALL
oncogene located at 2q22 in these two immature/ETP-ALL
patients. In order to identify the presumed oncogene, subsequent
breakpoint mapping was performed using FISH probes within
chromosome band 2q22, allowing us to map the breakpoint
within the vicinity of the ZEB2 locus (Fig. 1b). Next, we screened
an independent T-ALL cohort, comprising of 1,084 patients and
identified two additional T-ALL patient samples with an identical
t(2;14)(q22;q32) translocation. Taken together, we identified a
novel and rare, but recurrent translocation involving ZEB2 and
BCL11B in human T-ALL.
ZEB2 levels are elevated in human immature/ETP-ALL.
Microarray-based genome-wide expression studies have shown
that T-ALL encompasses distinct molecular groups with defined
gene expression signatures. Several key genes, such as LYL1,
MEF2C and HHEX, show elevated levels of gene expression in the
immature/ETP-ALL subclass3–6 as compared with other T-ALL
subtypes. Gene expression profiling data were available for one of
the four t(2;14)(q22;q32) cases (TL88)4, and showed an
immature/ETP-ALL gene signature. ZEB2 mRNA levels in this
particular patient were increased as compared with mature
T-ALL subclasses, but within the same range to other immature/
ETP-ALL patients without t(2;14)(q22;q32) translocations
(Supplementary Fig. 1a). BCL11B levels in the TL88 sample
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Figure 1 | Identification of ETP-ALL cases with translocations involving
the ZEB2 locus and enhanced ZEB2 expression in the immature subtype
of human T-ALL patients. (a) Partial karyotype (RHG banding) in case
TL88 showing a t(2;14)(q22;q32) translocation. (b) Dual-colour FISH
analysis using combination of BCL11B and ZEB2 probes on metaphase
spreads from leukaemic cells in case TL88. FISH probe RP11-68I8 is shown
in green, RP11-889B13 in red. Scale bar, 10mm. (c) ZEB2 expression levels in
a previously published4 cohort of 64 human paediatric T-ALL cases.
Unsupervised hierarchical classification of T-ALL subtypes was based on
gene expression and genomic annotations. Mean expression is indicated
and Mann–Whitney U-Test used for statistical analysis. (d) ZEB2 expression
levels in an independent published cohort of 57 human adult T-ALL cases.
Unsupervised hierarchical classification of immature and mature subclasses
was based on gene expression and genomic annotations as reported17.
Mean expression is indicated and Mann–Whitney U-Test used for statistical
analysis. (e) Heatmap showing expression levels of the miRNA-141/200c
cluster in a published cohort of human T-ALL patients48. (f) qRT–PCR
analysis; relative mRNA expression for ZEB2 and the immature marker
genes LYL1, HHEX, MEF2C, PSCD4, FAM46A in six human T-ALL cell lines.
Data were presented as average±s.d.
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were not significantly lower as compared with other immature/
ETP-ALL samples (Supplementary Fig. 1b).
Analysis of gene expression profiles from paediatric16 and
adult17 T-ALL patient series confirmed that ZEB2 expression
levels were predominantly higher (Fig. 1c,d), and inversely
correlated with the lower levels of miR200c (Fig. 1e) within
immature/ETP-ALL patients.
Moreover, real-time quantitative PCR (qRT–PCR) analysis
confirmed high ZEB2 expression in LOUCY cells (Fig. 1f), a
T-ALL cell line with a transcriptional signature highly similar to
that of immature/ETP-ALL patients6,17 (Supplementary Fig. 2).
Taken together, the observed recurrent t(2;14)(q22;q34)
translocations involving the ZEB2 locus in combination with
high ZEB2 levels throughout human immature/ETP-ALL, suggest
that ZEB2 might act as an oncogenic driver in this subset of
human T-ALL.
Increased Zeb2 expression results in T-cell leukaemia in mice.
To further study the role of ZEB2 as a putative oncogene in the
pathogenesis of T-ALL, we crossed our recently developed con-
ditional ROSA26-based Zeb2 gain-of-function mouse model18
with the Tie2-Cre line19. Upon Cre expression and removal of the
floxed stop cassette (Fig. 2a) in all endothelial and haematopoietic
cells19,20, a bicistronic transcript encoding ZEB2 and the
enhanced green fluorescent protein reporter (EGFP) is
expressed from the ROSA26 promoter. Heterozygous Zeb2
overexpression (R26-Zeb2tg/þ ) resulted in twofold upregulation
of the total thymic Zeb2 mRNA levels (Fig. 2b). Homozygous
R26-Zeb2tg/tg mice displayed a doubling of transgene expression
leading to a three- to fourfold Zeb2 mRNA upregulation (Fig. 2b).
R26-Zeb2tg/tg mice (n¼ 21) can survive until adulthood and
peripheral blood analysis from 6- to 8-week-old mice revealed no
significant difference in blood cell composition at this age
(Supplementary Fig. 3). R26-Zeb2tg/tg mice, however, start to die
from 5 months of age onwards, with 53% of these mice dying by
15 months of age (Fig. 2c). At autopsy, mediastinal masses were
detected (Fig. 2d). Detailed pathological examination diagnosed
these mice with precursor T-cell lymphoblastic leukaemia (Pre-T
LBL) as determined by immunohistochemistry: CD45/CLAþ ;
CD3þ ; CD45/B220 and IBA-1 with the presence of cKitþ
cells (Fig. 2e). The Pre-T LBL likely originated from the thymus
with sheets composed of medium to large-sized lymphoid cells
infiltrating into the surrounding tissues, including lung, heart and
cranial mediastinum and systemically into lymph nodes, liver,
spleen, kidney and bone marrow (Fig. 2f,g). Blood smears
detected a high percentage of atypical lymphoid cells in the
circulation (Fig. 2h).
To further investigate the oncogenic role of Zeb2 in the
progression of thymic tumours in a more robust manner with
increased penetrance, we crossed our Tie2-cre, R26-Zeb2 double
transgenic mouse model onto a p53fl/fl background21, which is
prone to develop thymic tumors. In addition, the p53 model
allowed us to further investigate potential synergism with other
aberrantly expressed genes in malignant T-cell development.
These mice are denoted as control P53/R26þ /þ and Zeb2-
overexpressing P53/R26-Zeb2tg/þ or P53/R26-Zeb2tg/tg mice/
tumours for the remainder of this study. A significant and
dosage-dependent decrease in tumour latency (Fig. 2i) and a clear
shift in tumour spectrum were observed upon overexpression of
Zeb2 on a p53 knockout background. Control P53/R26þ /þ mice
developed neoplastic lesions from both vascular (40.5%) and
haematopoietic origins (54.8%)22, mainly T-cell lymphomas, at
an average age of 25.5 weeks (Supplementary Table 1). P53/R26-
Zeb2tg/þ or P53/R26-Zeb2tg/tg mice developed tumours
significantly faster, after 15.5 and 12.7 weeks, respectively, and
with a complete shift towards haematopoietic neoplastic lesions
(100%), mainly precursor T-cell lymphoma (85.7 and 87.5%;
Fig. 2j and Supplementary Table 1). No differences were observed
in leukaemia distribution and/or systemic organ involvement
between Zeb2-overexpressing and control mice (data not shown).
T-cell antigen receptor rearrangement analysis was suggestive of
either mono- or oligoclonal origin for all of the examined thymic
tumours irrespective of genotype (Supplementary Fig. 4).
To investigate the presence of cooperating mutations involved in
the pathogenesis of Zeb2-induced leukaemias, and to determine to
what extent this leukaemic mouse model recapitulates human
T-ALL, we performed mutation analysis and array Comparative
Genomic Hybridization profiling in control (P53/R26þ /þ ) and
Zeb2-overexpressing tumours (R26-Zeb2tg/tg and P53/R26-Zeb2tg/þ
or P53/R26-Zeb2tg/tg). We identified prototypical Notch1 mutations
(Supplementary Fig. 5a and Supplementary Table 2) as well as focal
deletions affecting the Pten and Ikzf1 loci (Supplementary Fig. 5b,c
and Supplementary Table 2).
To confirm the autocrine nature of this spontaneously arising
lymphoblastic leukaemia, Zeb2-overexpressing mice were crossed
with a T-cell-restricted CD4-cre line23. Here we were able to
recapitulate leukaemia development and confirm the T-cell origin
of this disease (Supplementary Fig. 6).
Zeb2-expressing thymomas have an immature/ETP-ALL sig-
nature. Next, we performed differential expression analysis on
P53/R26-Zeb2tg/tg vs control p53/R26-Zeb2þ /þ tumours using
Agilent microarray hybridization (Fig. 3a). Gene Set Enrichment
Analysis using the top-500 probe sets overexpressed in immature/
ETP-ALL patients, demonstrated that the gene expression profile
of the Zeb2-overexpressing mouse tumours significantly over-
lapped with that of human immature/ETP-ALL patients (Fig. 3b).
Zeb2-overexpressing thymic tumours lack mature T-cell markers
such as surface CD3 and CD8 and exhibited a higher percentage
of cells that expressed the stem/progenitor marker cKit or CD44,
when compared with the control P53/R26þ /þ -deficient tumours
(Fig. 3c). This increase in cKitþ cells in the Zeb2 overexpression
tumours was confirmed via immunohistochemistry (Fig. 3d and
Supplementary Table 3). qRT–PCR analysis for the immature
marker gene Lyl1 showed a significant overexpression in our P53/
R26-Zeb2tg/tg tumours compared with the control tumours
(Fig. 3e and Supplementary Fig. 7a). A similar trend could be
observed for other immature marker genes like Hhex and Mef2c
(Supplementary Fig. 7b). In addition, downregulation of the Ptcra
(Pre-T-cell Receptor alpha) mRNA levels could be observed upon
Zeb2 overexpression in the p53 null thymic tumours
(Supplementary Fig. 7c), similar to what is previously seen in
human5 and mouse24,25 immature/ETP-ALL.
Of note, in our control P53/R26þ /þ cohort (n¼ 39), one mouse
spontaneously developed a thymoma with immature T-ALL
characteristics; with low tumour latency, increased cKit protein
levels as well as high Lyl1, Hhex, Mef2c mRNA expression that all
correlated with elevated endogenous Zeb2 levels (Supplementary
Fig. 8). These results suggest that immature ETP-ALL-like T-ALL
can develop spontaneously in p53 knockout mice.
Zeb2 modulation affects leukaemic cancer stem cell properties.
The increased expression of cKit and Lyl1 suggested the presence
of more leukaemic stem cells upon Zeb2 overexpression. To
further investigate whether there may be differences in leukaemic
cancer stem cell properties between P53/R26þ /þ control and
P53/R26-Zeb2tg/þ or P53/R26-Zeb2tg/tg tumours, we performed
serial dilution tumour transplantation experiments in immuno-
deficient NOD/SCID mice. This analysis revealed a 60-fold
increase in leukaemia-initiating cells in the P53/R26-Zeb2tg/þ -
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms6794 ARTICLE
NATURE COMMUNICATIONS | 6:5794 | DOI: 10.1038/ncomms6794 |www.nature.com/naturecommunications 3
& 2015 Macmillan Publishers Limited. All rights reserved.
Targeted conditional Rosa26 locus
R
el
at
iv
e 
Ze
b2
 m
RN
A
le
ve
ls
R
el
at
iv
e 
eG
FP
m
RN
A
le
ve
ls
***
***
***
ROSA26 5 ′ ROSA26 3 ′IRES-EGFPmZEB2
SA
PGK -Neo -3XpA+
loxP
Cre-mediated expression
from Rosa26 locus
Cre
recombination
loxP
ROSA26 5 ′ ROSA26 3 ′IRES-EGFPmZEB2
loxP
SA
*
CD3H&E
cKit IBA-1 CD3
Liver
CD3
Lung Bone marrow
H&E
Blood smear
MG Giemsa
0.0
0
50
100
Control (n=9)
Tie2cre, R26-Zeb2tg/+ (n=15)
Tie2cre, R26-Zeb2tg/tg (n=21)
Pe
rc
en
t s
ur
vi
va
l
Months
Log rank P=0.0015**
0
50
100
P53/R26+/+ (n=39)
P53/R26-Zeb2tg/+ (n=40)
P53/R26-Zeb2tg/tg (n=16)
Control (n=10)
Log rank P<0.0001***
Pe
rc
en
t s
ur
vi
va
l
Vascular
Myeloid leukemia
B-cell lymphoma
T-cell lymphoma
Weeks
5
4
3
2
1
0
Co
ntr
ol
R2
6-Z
eb
2t
g/+
R2
6-Z
eb
2t
g/t
g
Co
ntr
ol
R2
6-Z
eb
2t
g/+
R2
6-Z
eb
2t
g/t
g
P5
3/R
26
-Ze
b2
tg/
+
P5
3/R
26
+/+
P5
3/R
26
-Ze
b2
tg/
tg
0
2
4
6
8
10
12
14
16
18
20
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
Miscelaneous
2.5 5.0 7.5 10.0 12.5 15.0
50403020100
Figure 2 | Tie2-Cre-mediated expression of Zeb2 on its own or in synergy with p53 loss leads to T-cell lymophoblastic leukaemia. (a) Schematic
representation of the conditional ROSA26-based Zeb2 overexpression mouse model. The mouse Zeb2 open reading frame was targeted to the ROSA26 locus
preceded by a floxed (fl) transcriptional stop (PGK-Neo-3XpA) cassette and followed by IRES-EGFP reporter sequence. (b) Quantification of relative Zeb2 and
EGFP mRNA levels in thymus of Tie2cre, R26-Zeb2tg/þ (R26-Zeb2tg/þ ) and Tie2cre, R26-Zeb2tg/tg (R26-Zeb2tg/tg) mice compared with Tie2-Cre-negative
control littermates (Control). qRT–PCR data were presented as average±s.d. (c) Kaplan–Meier survival curve of R26-Zeb2tg/tg mice (n¼ 21) compared with
control littermates (n¼9). Mantel–Cox test was used for statistical analysis. (d) From 5 months of age, R26-Zeb2tg/tg spontaneously develop thymus tumours
(asterisk). (e) Histopathological analysis of thymic mass displaying dense monomorphic sheets of neoplastic lymphoid cells; haematoxylin and eosin (H&E)
staining, scale bar, 100mm. Neoplastic lymphoid cells are diffusely positive for the T-cell marker CD3; CD3 immunohistochemistry, scale bar, 80mm.
Neoplastic Tcells also exhibit moderate degree of cKit expression; cKit immunohistochemistry, scale bar, 100mm. IBA-1-positive histiocytes/macrophages are
scattered among the neoplastic lymphoid sheets; IBA-1 immunohistochemistry, scale bar, 100mm. (f) Precursor T-cell lymphoblastic leukaemia (Pre-T LBL)
invading the adjacent pulmonary parenchyma with dense infiltrates of CD3-positive cells expanding the peribronchial/perivascular interstitium; CD3
immunohistochemistry, scale bar, 400mm. PTLL exhibits systemic dissemination with dense infiltrates of CD3-positive cells expanding the centrilobular and
portal areas and dissecting along the surrounding hepatic cords; CD3 immunohistochemistry, scale bar, 200mm. (g) Bone marrow of R26-Zeb2tg/tg with Pre-T
LBL. H&E stain, scale bar, 50mm. (h) Microscopic analysis of blood smears from R26-Zeb2tg/tg with Pre-T LBL, with a high number of large and atypical
leukaemic lymphoid cells in the circulation. May Grunwald Giemsa stain, scale bar, 50mm. (i) Kaplan–Meier survival curve after intercrossing Zeb2-
overexpressing mice on to a Tie2cre, p53f/f thymic tumour-prone background: a significant decrease in tumour latency and survival could be observed (j) with
a shift in tumour spectrum. Mantel–Cox test was used to determine significance for Kaplan–Meier curve. **Po0.01, ***Po0.001.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms6794
4 NATURE COMMUNICATIONS | 6:5794 | DOI: 10.1038/ncomms6794 |www.nature.com/naturecommunications
& 2015 Macmillan Publishers Limited. All rights reserved.
and P53/R26-Zeb2tg/tg-overexpressing tumours (0.33 leukaemic
stem cell (LSC) per 103 tumour cells) compared with the P53/
R26þ /þ control tumours (0.50 LSC per 105 tumour cells)
(Fig. 4a). Similar differences were obtained by transplanting the
derived mouse cell lines, suggesting that the increased leukaemia-
initiating capacity is maintained upon in vitro culturing (Fig. 4b).
In addition, a 65% knockdown of ZEB2 in the luciferase-positive
human immature-like T-ALL cell line LOUCY resulted in
decreased tumour formation when transplanted into NOD/SCID/
Il2Rg null recipients (Fig. 4c and Supplementary Fig. 9a,b).
Zeb2 overexpression results in increased Il7r expression. Based
on our microarray expression analysis and focusing on genes
previously identified as recurrently mutated in immature/ETP-
ALL7, we found a significant and Zeb2 dosage-dependent increase
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in Il7r mRNA (Fig. 3a), which was confirmed by qRT–PCR
analysis (a 8.5-fold increase in the P53/R26-Zeb2tg/þ and a 17-fold
increase P53/R26-Zeb2tg/tg tumours compared with p53/R26þ /þ
control tumours; Fig. 5a). As a result, a strong positive correlation
(Pearson, r¼ 0,787 was seen between Zeb2 and Il7r mRNA
expression levels in our mouse (Fig. 5b and Supplementary
Fig. 10a) and human (Pearson, r¼ 0.735) immature/ETP-ALL
tumours (Fig. 5c and Supplementary Fig. 10b).
To functionally validate the observed correlative expression
between ZEB2 and IL7R in immature subtypes of human T-ALL,
we performed short interfering RNA (siRNA)-mediated knock-
down of ZEB2 in the immature/ETP-ALL-like cell line LOUCY.
ZEB2 knockdown resulted in a significant downregulation of the
IL7R mRNA levels (Fig. 5d), confirming the regulation of IL7R
expression by ZEB2 in human leukaemic blasts. Moreover, the
amplification of a phylogenetically conserved Il7r promoter
element was enriched in a chromatin immunoprecipitation
(ChIP) experiment using a ZEB2-specific monoclonal antibody,
suggestive of direct binding of ZEB2 to this Il7r promoter element
(Fig. 5e). However, ZEB2 overexpression experiments in
JURKAT, a mature T-ALL cell line that lacks the characteristic
immature/ETP-ALL mRNA expression profile, did not yield any
correlated expression with IL7R (Supplementary Fig. 10c),
suggesting that an ETP-ALL-specific co-factor might be essential
for the ZEB2-mediated effects on IL7R gene expression.
ZEB2-induced Il7r upregulation promotes T-ALL cell survival.
To functionally investigate the effects of increased Il7r levels and
its downstream signalling by ZEB2, we initially tested the IL-7
effects on LOUCY cells with and without ZEB2 knockdown. Also
here a proportional decrease in IL7R levels could be observed
(Supplementary Fig. 9b). However, as this cell line has lost its IL-7
responsiveness, we were unable to make use of this cell line to
further study the functional links between ZEB2 and IL7R sig-
nalling (Supplementary Fig. 9c–e).
To circumvent this issue, we utilized mouse T-ALL cell lines
derived from two P53/R26þ /þ control, one P53/R26-Zeb2tg/þ
and four P53/R26-Zeb2tg/þ and P53/R26-Zeb2tg/tg tumours.
The Zeb2-overexpressing T-ALL cell lines have correlated
increased Il7r mRNA and cell surface IL7R protein levels
compared with the control cell lines (Supplementary Fig. 11a,b).
In these cell lines, we monitored phosphorylated STAT5 (P-
STAT5) levels, with and without recombinant IL-7 administration.
Addition of the IL-7 ligand increased P-STAT5 levels in both
Zeb2-overexpressing T-ALL cell lines, whereas no or minimal
effect was observed in the two control cell lines (Fig. 5f). The latter
might be associated with the differences in tumour immunophe-
notype between control P53/R26þ /þ and P53/R26-Zeb2tg/tg cells
(Supplementary Fig. 11c). We conclude that the IL-7/STAT5
pathway is not mutated or constitutively activated in the Zeb2-
overexpressing T-ALL cell lines, and remains responsive to ligand-
induced activation. A similar increased level of P-STAT5 could be
observed in primary tumour samples (Fig. 5g).
Effects of interfering with ZEB2-mediated IL-7-JAK-STAT
axis. Based upon previous findings26,27, we hypothesized that
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Zeb2-overexpressing T-ALL cells (P53/R26-Zeb2tg/þ or P53/R26-
Zeb2tg/tg) may be dependent upon IL-7 for optimal growth
and/or survival. Indeed, we observed increased cell survival
of the P53/R26-Zeb2tg/tg T-ALL cell line in response to
exogenous administration of IL-7, whereas only a minimal
effect was observed in the control P53/R26þ /þ cells (Fig. 5h).
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This in vitro pro-survival effect could be abolished through
the use of a monoclonal IL7R-blocking antibody (A7R34; Fig. 6a)
or the JAK1/2 inhibitor Ruxolitinib (RUX; Fig. 6b),
and was accompanied by the loss of increased levels of
P-STAT5 as well as phosphorylated AKT and GSK3b another
pathway activated by IL-7 (Fig. 6c). No IL-7-dependent
effects were seen on the proliferation rate of the cells (data
not shown).
To test whether increased Il7r levels upon Zeb2 upregulation
are involved in the survival of the injected lymphoblast cells and
enhanced leukaemia initiation, we transplanted Zeb2-overex-
pressing mouse cell lines (P53/R26-Zeb2tg/tg) with and without
IL7R-blocking antibody (A7R34) administration. Extended
survival of the transplanted NOD/SCID in the A7R34-treated
animals was seen (Fig. 6d), indicating that enhanced Il7r levels
and its downstream signalling is contributing to the increased
leukaemia-initiating capacity of the Zeb2-overexpressing
tumours.
Discussion
Whole-genome expression profiling of T-ALL patients has
defined immature/ETP-ALLs as a distinct entity4–6,
characterized by a poor response to current treatment regimens.
A recent whole-genome sequencing study suggested that this
immature T-ALL subgroup is genetically heterogenous, and
although multiple recurrent genomic lesions have recently been
identified7, the molecular drivers and therapeutic targets remain
elusive. Here we provide compelling evidence for an oncogenic
driver role for ZEB2 through gain-of-function mechanisms in
immature/ETP-ALL development.
First, we observed increased ZEB2 levels in the paediatric and
adult immature/ETP-ALL subclass and identified a rare but
recurrent t(2;14)(q22;q32) translocation in a few of these typical
ETP-ALL cases. This novel translocation, results in juxtaposition
of the promotor and proximal portion of the BCL11B locus to the
ZEB2 locus, a finding reminiscent of previously described
BCL11B-driven T-ALL oncogene activation12,13. These data are
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strongly indicative for an oncogenic driver role for ZEB2 in
T-ALL, and is consistent with previously reported retroviral
mutagenesis screens28–30 that have suggested Zeb2 involvement
in leukaemogenesis. Whether or not loss/alternative functions of
BCL11B are involved in leukaemia initiation/progression
specifically in these patients remains unknown. Importantly,
other mechanisms are involved in ETP-ALL patients leading to
ZEB2 upregulated expression levels besides these rare recurrent
translocations. One potential mechanism may be related to
altered expression of miR200c, which have previously been shown
to negatively regulate Zeb family member expression11,31 and to
be altered in cancer settings. Exactly how miR200c levels are
downregulated to begin with remains to be determined but may
be related to changes in the promoter methylation status as has
been previously shown in other tumour types32,33.
Using a ROSA26-based overexpression of Zeb2 in the
endothelium and throughout the entire haematopoietic system
induces formation of precursor T-cell lymphoblastic leukaemia.
Using the T-cell-restricted CD4-Cre line to overexpress Zeb2
recapitulated the spontaneous thymoma formation and strongly
suggests a cell autonomous role of Zeb2, however, given the
paracrine effects associated with Zeb2 deletion in the central
nervous system34, we cannot exclude environmental involvement
in the observed T-cell lymphoma formation phenotype.
Intercrossing onto a p53-deficient background drastically
accelerated tumour formation and shifted the tumour spectrum
towards an immature precursor T-cell lymphoblastic leukaemia,
with an expression profile similar to ETP-ALL patients. Mouse
tumours showed prototypical activating mutations affecting
Notch1 and loss of the tumour-suppressor genes Pten and Ikzf1,
supporting the fact that the p53 null Zeb2 transgenic mouse
model closely recapitulates human T-cell leukaemia35–37, and is
in keeping with the higher occurrence of IKZF1 mutations in
ETP-ALLs7.
In line with a presumed ETP-ALL phenotype for the mouse
Zeb2-driven leukaemias, we also observed increased LSC proper-
ties. These enhanced LSC characteristics associated with Zeb2
overexpression are in line with previous observations that
expression of the ZEB family members is correlated with poor
prognosis of solid tumours8,38, putatively in part through the
acquisition of enhanced cancer stemness programmes10,11.
Mechanistically, we demonstrate that ZEB2 leads to upregu-
lated IL7R expression in immature/ETP-ALL cells. A strong
positive correlation was observed between Zeb2 and Il7r mRNA
levels in our mouse model and in the human LOUCY cell line,
which exhibits an ETP-ALL-like phenotype. IL-7 signalling is of
key importance in normal thymocyte maturation and differentia-
tion and constitutive activation of IL7R-driven signalling has
been shown to lead to T-ALL oncogenesis. In approximately 10%
of T-ALLs, including ETP-ALLs7,39–41, activating mutations in
the IL7R gene are present representing an interesting drugable
target for novel treatment using IL7R-blocking antibodies or
more novel compounds for the inhibition of downstream
JAK/STAT5 signalling27, like RUX. Previous studies have
demonstrated that use of blocking IL-7 antibodies or use of
IL-7-deficient mice could dramatically decrease human T-ALL
formation in xenotransplantation settings using immuno-
compromised mice27,42. Here we could see a clear IL-7-
dependent survival effect of the derived Zeb2-overexpressing
mouse T-ALL cell lines in vitro and an effect on their ability to
initiate secondary tumours after transplantation. Whether the
described ZEB2-IL7R axis is also important in human ETP-ALL
disease progression remains to be tested.
In conclusion, we have found that sustained overexpression of
Zeb2 acts as a leukaemic driver for immature T-ALLs with
increased leukaemic stem cell properties. ZEB2-mediated
upregulation of Il7r expression and activation of the JAK/STAT
pathway represents a possible therapeutic target for this
aggressive and chemoresistant subtype of human T-ALL.
Methods
Patients. Conventional karyotyping was performed in bone marrow samples at
T-ALL diagnosis. Patients TL88 and Case #2 were both adults. Karyotype was
46,XY,t(2;14)(q22;q32)[20] in both cases. Leukaemic cells immunophenotype was
as follows for TL88: CD2þ , CD5weak, CD7þ , CD3icþ , CD4 , CD8 , CD34þ ,
CD13þ , CD33 , CD10 , B-cell marker negative; and Case #2: CD2þ , CD5weak,
CD7þ , CD3icþ , CD34þ , CD33 , CD13þ , B-cell markers negative. Patients
provided informed consent to use leftover material for research purposes according
to the Helsinki Declaration. This study was approved by the Institutional Review
Board of the Institut Universitaire d’He´matologie, Paris, France.
Two other T-ALL patients with a similar translocation were identified via
conventional karyotype analysis in a an independent cohort: Case #3 (43-year-old)
46,XY,t(2;14)(q23;q32)[19]/ 46,idem,del(6)(q?13q?15)[17]/46,XY[2] and Case #4
(6-year-old) 46,XY,þY,t(2;14)(q23;q32),del(7)(q3?6),del(9)(q22),-12,der(19)
t(12;19)(q13;?p/q)[7]. Also for these patients, local ethical committee approval was
obtained by the treatment centre and informed consent was given according to the
Helsinki Declaration.
Animal experimentation and handling. All experiments were performed
according to the regulations and guidelines of the Ethics Committee for care and
use of laboratory animals of Ghent University. The mouse (Mus musculus) cohorts
used in these experiments were sibling littermates and were maintained on a mixed
CD1 outbred genetic background and randomly grouped into control and
experimental groups based upon their genotypes. Both male and female mice were
included in the various analyses and ranged in age from 3 to 60 weeks.
For the transplantation experiments, primary thymic tumours were dissected
under aseptic conditions. Cell concentrations were measured using Burker cell
counter chamber. A dilution series was prepared in sterile PBS and the indicated
cell numbers were intravenously injected in 6- to 10-week-old NOD/SCID
recipient mice (Charles River). A similar approach was used for the transplantation
of the derived murine cell lines. Three or four primary tumours per genotype and
at least two independent cell lines/genotype were used.
For the transplantation experiments in combination with IL7R-blocking
antibody, 2 106 P53/R26-Zeb2tg/tg cells in sterile PBS were intravenously injected
in eight NOD/SCID recipient mice (Charles River). After injection, the mice were
randomly divided in two groups, and treatment was started. For 3 weeks after
transplantation, mice were intraperitoneally injected every second day with 450 mg
IL7R-blocking antibody (A7R34; BioXCell) or 450 mg isotype control antibody
(2A3; BioXCell) in case of the control group.
5 106 luciferase-labelled LOUCY cells in sterile PBS were injected in 6-week-
old (NSG KO mice) via the tail vein (n¼ 3 per cell line). At regular time points, the
bioluminescence was measured using the IVIS Lumina II imaging system (Perkin
Elmer). Before imaging, the mice were injected intraperitoneally with 200 ml of a
15mgml 1 firefly D-Luciferin potassium salt solution and anaesthetized by
inhalation of 5% isoflurane. The mice were imaged 10min after Luciferin injection.
Transplantation experiments using leukaemic cell lines were not repeated in order
to reduce the number of laboratory animals used on request of the ethical
committee of Ghent University.
Mouse pathology. A complete necropsy was performed on each mouse included
in Supplementary Table 1. Pathological and histological examination were per-
formed in a blinded manner. Tissue samples were formalin-fixed, paraffin-
embedded, sectioned and stained with haematoxylin and eosin for histopatholo-
gical examination. Additional immunohistochemical (IHC) analysis was performed
when necessary.
Samples of gross lesions, brain, skin, salivary glands, trachea, oesophagus,
thyroids, lungs, heart, spleen, liver, kidneys, pancreas, gastrointestinal tract,
thymus, lymph nodes (cervical, pancreatic and mesenteric), urogenital tract,
adrenals and lumbar vertebrae (bone marrow) were formalin-fixed, paraffin-
embedded, sectioned at 4 mm and stained with haematoxylin and eosin for
histopathological examination. Additional IHC analyses were also performed in
order to better characterize the origin of the neoplastic lesions encountered. Details
concerning the panel of IHC stains applied are reported in Supplementary Table 4.
The different categories of lymphoid and vascular tumours were defined according
to the diagnostic criteria proposed by Morse et al.43 and Rehg and Ward44,
respectively. Detailed definition of tumour categories is given below:
Pre-T LBL: thymic: Pre-T LBL characterized by primary thymic involvement
with different degree of local invasion (for example, mediastinum, lungs and heart)
but without distant spread to extrathoracic organs/tissues. Immunophenotype (as
determined by means of immunohistochemistry): CD45/CLAþ ; CD3þ ; cKit þ *;
CD45/B220 ; CD20 ; IBA-1 .
Pre-T LBL/L: generalized/systemic: Pre-T LBL//leukaemia characterized by
primary thymic involvement with different degree of local invasion (for example,
mediastinum, lungs and heart) and distant spread to/involvement of extrathoracic
organs/tissues including spleen, superficial and internal lymph nodes, bone
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marrow, liver and kidneys. Increased white blood cell count with more than
20% of immature and atypical lymphoid form was also documented in peripheral
blood of some cases. Immunophenotype (as determined by means of immuno-
histochemistry): CD45/CLAþ ; CD3þ ; cKitþ *; CD45/B220; CD20 ; IBA-1 .
Uncharacterized (non-thymic) T L: multicentric: not otherwise characterized
T-cell lymphoma with primary involvement of superficial and internal lymph
nodes, gut associated lymphoid tissue (GALT) and spleen. The neoplasm displays
different degree of local invasion and massive spread to liver, kidneys, lungs,
pancreas, gonads and central nervous system. Thymus and bone marrow are
distinctively spared. Immunophenotype (as determined by means of
immunohistochemistry): CD45/CLAþ ; CD3þ ; CD45/B220 ; IBA-1 .
ML: myeloid leukaemia with neutrophilic differentiation arising from bone
marrow and spleen and with different degree of hepatic, renal and nodal
involvement. Leukaemic population in affected organs is mainly composed of
myeloblasts and immature granulocytic forms (promyelocytes and myelocytes).
Increased white blood cell count with prevalence of myeloblasts and immature
neutrophilic forms is also evident in the peripheral blood.
SMZL: sSplenic marginal zone lymphoma. Immunophenotype (as determined by
means of immunohistochemistry): CD45/CLAþ ; CD3 ; CD45/B220þ ; IBA-1 .
HMA: haemangioma, solitary begnign neoplasm of vascular endothelial origin
(CD31þ and Lyve1 immunohistochemistry) arising from mediastinum or
retroperitoneal space.
HSA solitary: haemangiosarcoma, solitary malignant neoplasm of vascular
endothelial origin (CD31þ and Lyve1 immunohistochemistry) arising from
retroperitoneal space or subacutis/muscular fascia of the trunk.
HSA multicentric: multicentric HSAs, multiple malignant neoplasms of vascular
endothelial origin (CD31þ and Lyve1 immunohistochemistry) arising
simultaneously from two or more of the following locations: subacutis/muscular
fascia of the trunk, heart, liver, spleen, gonads.
HSA multicentric with metastases: —multicentric HSAs, multiple malignant
neoplasms of vascular endothelial origin (CD31þ and Lyve1
immunohistochemistry) arising simultaneously from heart and subacutis/muscular
fascia of the trunk and metastasizing to the lungs.
PA: solitary pulmonary adenoma.
IPA: solitary intestinal polypoid adenoma.
NGCO: solitary nongestational choriocarcinoma of the ovary.
*Variable degree of cKit expression with occasional negative cases. According to
Rehg et al.45, neoplasms with consistent cKit expression can be classified as early
Pre-T LL/L (presumably originating from CD4, CD8 double negative (DN)
thymocytes), whereas neoplasms with minimal or negative cKit expression should
be considered as late Pre-T LL/L (presumably originating from DN thymocytes).
For IHC details see Supplementary Table 4.
Flow cytometry. Cells were analysed by LSRII (BD Biosciences) and FACSDiva or
FlowJo software (BD Biosciences). Cell debris and cell aggregates were gated out,
dead cells were discarded using Propidium Iodide or the fixable Viability Dye
eFluro506 (eBioscience). Antibodies used for flow cytometry are listed in
Supplementary Table 5. Intracellular stainings were done using BD Cytofix/
Cytoperm kit (BD Bioscience) according to the manufacturer guidelines.
Cell culture. Primary mouse thymic lymphoma cell lines were generated according
to the previously published protocols46. In short, thymus tumours were dissected
under aseptic conditions and plated in RPMI medium supplemented with 10%
heat-inactivated fetal bovine serum (Sigma), penicillin (100Uml 1)-streptomycin
(100 mgml 1), 2mM L-glutamine (Gibco), 0.05mM 2-mercaptophenol and where
indicated 5 ngml 1 recombinant IL-7 (Peprotech) and incubated at 37 C with 5%
CO2 and 95% humidity. After 4–5 passages, stable cell cultures were obtained and
freezings were made for further use.
For IL-7 effects on cell survival and proliferation, 3 106 primary T-ALL cells
were labelled with 5 ngml 1 Cell Proliferation Dye eFluor670 (eBioscience) for
10min at 37 C, washed three times with cold medium and seeded at a
concentration of 1 106 cell per ml in medium with or without 5 ngml 1 IL-7
and incubated at 37 C, 5% CO2 and 95% humidity. Every second day, the
percentage of surviving cells was quantified using the fixable Viability Dye
eFluro506 (eBioscience) and flow cytometry. Where indicated JAK1/2 signalling
was inhibited by administration of RUX phosphate (INCB018424; InvivoGen).
A stock solution of 20mM RUX was prepared in dimethylsulphoxide and diluted
in growth medium to a working dilution of 1 mM. Where indicated, IL7R signalling
was blocked by administration of 100mgml 1 A7R34-blocking antibody
(BioXCell). As a control, we used 100 mgml 1 isotype control antibody 2A3
(BioXCell). These in vitro cell survival experiments were performed on at least two
independent primary cell lines/genotype and repeated twice/experiment.
The LOUCY cell line (DSMZ, Germany) was cultured in RPMI-1640 media
supplemented with 10% fetal bovine serum, 100Uml 1 penicillin G, 100mgml 1
streptomycin, 100mgml 1 kanamycin and 2mM L-glutamine at 37 C in a
humidified atmosphere under 5% CO2. For siRNA-mediated knockdown
experiments, we performed electroporation in triplicate of 400 nM ZEB2-specific
siRNAs (siZEB2-01: ON-TARGETplus Human ZEB2 siRNA J-006914-07,
siZEB2-02: Thermo Scientific; Silencer Select Pre-designed Human ZEB2 siRNA
s19034, Life Technologies) or 400 nM of scrambled siRNAs (si-Ctrl: siGENOME
Non-targeting siRNA pool #2, Thermo Scientific) as control. Also electroporation
without adding siRNAs was performed as control (no siRNA). For the
electroporation, an exponential decay pulse (300V, 1,000mF; Genepulser MxCell,
Bio-Rad) was used. After 72 h, RNA was isolated and evaluated by qRT–PCR.
Results were presented as mRNA expression relative to control electroporation
results. siRNA knockdown results where siRNA did not result in a proper Zeb2
knockdown were excluded.
Luciferase-positive LOUCY cells were generated by infecting the LOUCY cell
line with a PWPI-LUC lentivirus. Non-concentrated virus was produced in
HEK293TN cells using JetPEI polyplus reagent with pMD2.G (envelope plasmid),
psPAX2 (packaging plasmid) and pWPI-LUC (target plasmid) in 0.1/0.9/1 ratios.
Luciferase activity was verified in vitro using the Dual-Luciferase Reporter Assay kit
(Promega). Stable knockdown for ZEB2 in LOUCY were generated as described
previously47. Lentiviral particles were generated using pLV-TH shZEB2(SEC8) or
the pLV-TH empty vectors. Transduction efficiencies were determined by
measuring enhanced green fluorescent protein (EGFP) expression using flow
cytometry. Subsequently, the cells were sorted using a FACSAria II machine (BD
Biosciences) to obtain cell populations with more than 90% EGFP-positive cells. All
original T-ALL cell lines were obtained from the DSZM (http://www.dsmz.de/) at
the start of this study and tested and found to be free of mycoplasma
contamination.
Real-time quantitative PCRs. Total RNA was isolated using RNeasy Plus Mini
Kit (Qiagen). cDNA was synthesized using the First Strand cDNA Synthesis Kit
(Roche) with oligo(dT) primer, starting from equal amounts of RNA. qRT–PCRs
were performed using the LightCycler 480 SYBR Green I Master (Roche), mon-
itored on a LichtCycler 480 system (Roche) and analysed using qBase software
from Biogazelle. Gene expression was standardized against housekeeping genes
b-actin, glyceraldehyde-3-phosphate dehydrogenase (Gapdh), RPL13 and TBP. All
primers used are listed in Supplementary Table 6. In the qRT–PCR analysis of
human T-ALL patients, results of two mature T-ALL and one immature T-ALL
cases were excluded because of high variability within the housekeeper genes or
between technical replicates, most probably due to low RNA quality.
Gene expression profiling. For human T-ALL patients, expression data of pre-
viously published gene expression profiling arrays of two independent cohorts of
T-ALL patients (one paediatric and one adult cohort) was used. The first cohort
consisted of bone marrow lymphoblast samples from 64 paediatric T-ALL patients
(15 immature, 25 TAL/LMO, 17 TLX1/TLX3 and 7 HOXA), which were collected
with informed consent according to the declaration of Helsinki from Saint-Louis
Hospital (Paris, France). Transcriptome profiling was performed on GeneChip
Human Genome U133 2.0 Plus arrays (Affymetrix) according to the standardized
procedures at the IGBMC (www.igbmc.fr, Strasbourg, France) and microarray data
files are available from ArrayExpress under accession no. E-MTAB-604 (ref. 16).
The second cohort consisted of 57 cryopreserved lymphoblast samples, which were
provided by the Eastern Cooperative Oncology Group. All samples were collected
in clinical trials E2993 and C10403. Gene expression profiling was performed using
the HumanHT-12 v4 Expression BeadChip (Illumina) and microarray data files are
available from the Gene Expression Omnibus accession nr GSE33469 (ref. 17).
Expression data of the mi-R141/200c cluster were obtained via a quantitative
PCR-based microRNA profilering study on 15 immature and 25 mature primary
T-ALLs48.
From the mouse leukaemia, RNA was isolated using the miRNeasy mini kit
with DNA digestion on-column (Qiagen). RNA concentration was measured on
the NanoDrop 1000 Spectrophotometer followed by RNA quality assessment by
use of the Experion Automated Electrophoresis System according to the
manufacturer’s instructions (Bio-Rad). Next, RNA samples were profiled for gene
expression analysis on SurePrint G3 Mouse 8 60K Microarrays according to the
manufacturer’s instructions (Agilent Technologies). Normalization of gene
expression data was done by quantile normalization using R. Differential gene
expression analysis was performed using fold change analysis and P-value
calculation based on unpaired t-test. Microarray data files are available from the
Gene Expression Omnibus accession number GSE62653. Gene set enrichment
analysis was executed against annotated gene set of a 500-probe set enriched in
human immature/ETP-ALL. Gene profiling was originally performed on three
P53/R26þ /þ vs three P53/R26-Zeb2tg/tg thymic tumours, however, one of the
control P53/R26þ /þ had spontaneously high levels of Zeb2 that occurred and was
therefore excluded from the control group. In all aspects, the phenotype of this one
control mouse tumour (decreased tumour latency, cKit expression, high Lyl1,
Mef2c, Hhex and Il7r expression) resembled the phenotype of the Zeb2-
overexpressing tumours, indicating that similarly high levels of Zeb2 can be
spontaneously observed in human and mouse immature T-cell lymphoblastic
leukaemias (Supplementary Fig. 8). This sample was also removed from the
qRT–PCR analysis depicted in Figs 4c and 5a and Supplementary Fig. 6.
Chromatin immunoprecipitation. P53/ROSA26-Zeb2tg/tg primary mouse T-ALL
cells were cross-linked in 1% formaldehyde for 10min at room temperature and
stopped with glycine (final concentration 0.125M). Cells were lysed in the presence
of protease inhibitors and DNA was sonicated. For immunoprecipitation, 100 mg
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DNA was used together with 3 ml of anti-ZEB2 monoclonal Ab49. Complexes were
precipitated with protein A and G Sepharose beads (GE Healthcare). Formaldehyde
cross-links were reversed by overnight incubation at 65 C and DNA was purified
using QIAquick PCR Purification Kit (Qiagen). Primers used are given in
Supplementary Table 6, including localization of the respective amplicon on the
mouse Il7r promotor (Supplementary Fig. 10c). Figure was generated using USCS
genome bioinformatics software (http://genome.uscs.edu/).
Western blotting. Protein lysates of IL-7 non-induced and induced (10 ngml 1,
30min) T-ALL cell lines were collected in Laemmli buffer (62.5mM Tris–HCl, pH
6.8; 10% glycerol; 2% SDS and 5% b-mercaptoethanol) containing phosphatase and
protease inhibitors (Roche) and sonicated before analysis. Total protein con-
centration was determined using DC Protein Assay (Bio-Rad). 40 mg per sample
was subjected to SDS–polyacrylamide gel electrophoresis, transferred onto a
membrane (Millipore) and used for detection. Primary antibodies used for
detection: rabbit polyclonal anti-STAT5 (1:1,000; #9363, Cell Signaling), rabbit
polyclonal P-STAT5(Tyr694) (1:1,000; #9351, Cell Signaling), mouse monoclonal
P-AKT(Ser473) (1:1,000; #4051S, Cell Signaling), rabbit monoclonal P-GSK3b
(Ser9) (1:1,000; #9323, Cell Signaling), rabbit polyclonal cMyc (1:1,000; #9402S,
Cell Signaling) and mouse anti-actin (1:10,000; clone C4, Molecular probes, Invi-
trogen). Anti-mouse and anti-rabbit IgG-HRP secondary antibodies (1:8,000;
Sigma-Aldrich) and the ECL detection kit (GE Healthcare) were used for detection.
Western blot quantifications were done using Fiji software. To rule out loading
differences, quantifications were normalized using signal detected for loading
control b-actin. Western blot analysis was performed on at least two independent
primary cell lines/genotype and repeated twice/experiment.
Images have been cropped for presentation. Full size images are presented in
Supplementary Fig. 12.
Mutation analysis on mouse tumour samples. Mutation analysis was performed
on Notch1 (exons 26, 27 and 34), Fbxw7 (exons 8, 9 and 11) and Pten (exons 5 and
7) as previously described50 and using primers shown in Supplementary Table 6.
Briefly, the PCR amplification mix consisted of 20 ng of DNA, 1 KapaTaq
reaction buffer (KapaBiosystems), 1U KapaTaq DNA polymerase, 0.2mM dNTP,
2.5 mM MgCl2, 0.2mM forward and reverse primer in a 25 ml of PCR reaction.
Next, following PCR protocol was performed: 10min at 95 C, 40 cycles (15 s at
96 C, 1min at 57 C and 1min at 72 C) and 10 at min 72 C. Finally, PCR
products were enzymatically purified followed by primer extension sequencing and
electrophoresis using ABI3730xl (Applied Biosystems).
Fluorescence in situ hybridization. Bacterial artificial chromosome (BAC) probes
were obtained from the Roswell Park Cancer Institute (https://www.roswellpar-
k.edu/shared-resources/genomics/services-and-fees/genomic-clone-distribution.
For the BCL11B locus at 14q32.2, flanking probes RP11-68I8, RP11-889B13 or
RP11-145P8, RP11-15E14 were used. To map the breakpoint locus on chromo-
some 2q22, sets of flanking probes were used in a chromosome walk on metaphase
spreads from case TL88, leading to map the ZEB2 locus. A second translocation
BCL11B-ZEB2 was then demonstrated in the second patient (Case #2) using
hybridization of combination of probes RP11-68I8, RP11-889B13, RP11-224H3
and RP11-67J2.
Statistics and general methods of data analysis. Kaplan–Meier survival curves
for the various mouse cohorts used in this study were generated with GraphPad/
Prism6 software and Log-rank (Mantel–Cox) test was performed for statistical
analysis. Groups of at least ten mice per cohort were randomly used per genotype
in order to obtain statistical significance.
Data analysis for differential expression analysis via real-time PCR was
performed using the qBaseþ (Biogazelle) or GraphPad/Prism6 software and
standardized against at least three housekeeping genes. Data were presented as
average±s.d. and indicated in the figure or figure legend. Comparison between two
data groups was done by two-sided Student’s t-test. One-way ANOVA test was
used for statistical analysis between three or more data groups. The Mann–
Whitney U-test was used to analyse differences in ZEB2 expression between genetic
subtypes of human T-ALL patients (microarray profile). The data sets used in the
various statistical analyses showed normal distribution around the mean and
similar variance between the groups that were being statistically compared. Unless
otherwise stated, all experiments were performed using at least three biological
replicates and experiments. *Po0.05, **Po0.01, ***Po0.001 (vs control).
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